Is hyperhomocysteinemia an important risk factor of cardiovascular disease?

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 5-6, 2003, Pages 345-347

  Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiovascular disease; Homocysteine; Hyperhomocysteinemia; Risk factors

Indexed keywords

HOMOCYSTEINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; STROKE; VEIN DISEASE; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS;

EID: 14044270042     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083826     Document Type: Conference Paper

References (23)

1. Cattaneo M. Hyperhomocysteinemia and thrombosis. Lipids 2001; 36 Suppl:S13-S26.
2. The Homocysteine Stuides Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta- analysis. JAMA 2002;288:2015-2022.
3. Epstein FH. The epidemiology of coronary heart disease: A review. J Chronic Dis 1965;18:735-774.
4. Wilhelmsen L, Wedel H, Tibbins G. Multivariate analysis of risk factors for coronary heart disease. Circulation 1973;48:950-958.
5. Rabkin SW, Sackett DL. Arterial Thromboembolism. Epidemiology. In: Colman RW, Hirsh J, Mrder VJ, Salzman EW, editors. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: J.B. Lippincott, 1987: 1273-1289.
6. Woo KS, Chook P, Lolin YI, Cheung ASP, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542-2544.
7. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-1121.
8. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36-37.
9. Bellamy MF, McDowell IFW, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Lewis MJ. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998;98:1848-1852.
10. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999;99:1156-1160.
11. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, Farzati B, Giugliano D. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281:2113-2118.
12. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999;100:1161-1168.
13. Chao C-L, Kuo T-L, Lee Y-T. Effects of methionine-induced hyperhomocysteinemia on emdothelium-dependent vasodilation and oxidative status in healthy adults. Circulation 2000; 101:485-490.
14. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta- analysis. JAMA 2002; 288:2023-2031.
15. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, den Heijer M, Kluijtmans LA, van den Heuvel LP et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-113.
17. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta- analysis. Circulation 1998; 98:2520-2526.
18. Yap S, Boers GHJ, Wilcken B, Wilcken DEL, Brenton DP, Lee PJ, Walter JH, Howard PM, Naughten ER. Vascular Outcome in Patients With Homocystinuria due to Cystathionine {beta}-Synthase Deficiency Treated Chronically: A Multicenter Observational Study. Arteriosclerosis, Thrombosis, and Vascular Biology 2001; 21:2080-2085.
19. O'Callaghan PA, Fitzgerald T, Tuomilheto J, Graham I. Homocysteine improves cardiovascular risk prediction modelling in a Finnish population. J Inherit Met Dis 2003; 26(suppl 1): 59 (abs.).
20. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998; 316:894-898.
21. Botto LD, Yang Q, Friedman JM. American Heart Association 44th annual Conference on Cardiovascular Disease Epidemiology and Prevention. San Francisco, March 5, 2004.
22. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99:178-182.
23. Cattaneo M. Homocysteine and cardiovascular diseases. Circulation 1999; 100:e151